Friday, February 16, 2007

McFadden on Part D

In today's Wall Street Journal (subscription required), Nobelist Dan McFadden describes his work assessing the impact of the new Medicare prescription drug benefit. His bottom line:
My overall conclusion is that, so far, the Part D program has succeeded in getting affordable prescription drugs to the senior population. Its privatized structure has not been a significant impediment to delivery of these services. Competition among insurers seems to have been effective in keeping a lid on costs, and assuring reasonable quality control. We do not have an experiment in which we can determine whether a single-product system could have done as well, or better, along these dimensions, but I think it is reasonable to say that the Part D market has performed as well as its partisans hoped, and far better than its detractors expected.